FDA Grants Priority Review for XTANDI® in Non-Metastati

/PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food...

Related Keywords

Canada , Japan , Tokyo , United States , America , American , Chris Boshoff , Ahsan Arozullah , Naoki Okamura , Prnewswire Pfizer Inc , Astellas Inc , Exchange Commission , Head Of Oncology Development , Astellas Pharma Inc , European Union , American Society Of Clinical Oncology , Drug Administration , Oncology Research , Pfizer , Lab Abnormalities , Medivation Inc , Astellas Pharma , Priority Review , New Drug Application , Prescription Drug User Fee Act , Chief Oncology Research , Development Officer , Executive Vice President , Senior Vice President , Oncology Development , Hazard Ratio , Confidence Interval , Pfizer Led Phase , South America , High Risk Biochemical , Reversible Encephalopathy Syndrome , Heart Disease , Fetal Toxicity , Drug Interactions , Full Prescribing Information , Pfizer Oncology , Focus Area Approach , Annual Report , Looking Information , Factors That May Affect Future , Accessed March , Prostate Cancer , Clin Pract , North America ,